iOncologi Secures U.S. Patent for RNA-Based Cancer Immunotherapy Platform

The United States Patent and Trademark Office has granted iOncologi a patent for an RNA-based method designed to improve tumor responsiveness to immune checkpoint inhibitor therapy, announced in a press release. The patent, owned by the University of Florida Research Foundation and licensed exclusively to iOncologi, supports the company’s UNIFYRs (Universal Immune Fortifying RNAs) platform.

The newly issued patent builds on findings published in *Nature Biomedical Engineering*, which described how non–tumor-antigen-specific mRNA formulations can boost type-I interferon responses and restore sensitivity to checkpoint inhibitors. These results were presented at the European Society for Medical Oncology (ESMO) 2025 Congress, where data showed that mRNA-based immune activation through SARS-CoV-2 vaccination correlated with improved survival in patients with melanoma and non–small cell lung cancer.

The UNIFYRs platform uses multilamellar RNA-lipid particles to reprogram immune responses and enhance checkpoint inhibitor efficacy across multiple solid tumor types. With the patent, iOncologi aims to expand development of RNA-based immunotherapies targeting resistance in cancer treatment.